MA-AMYLYX
26.10.2021 14:52:05 CEST | Business Wire | Press release
Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA). Ms. Hoffmann-Gendebien brings more than 20 years of leadership experience in the pharmaceutical and biotechnology industries with deep expertise in orphan drug development and commercialization. The first European entity of Amylyx, Amylyx Pharmaceuticals EMEA B.V., is incorporated in the Netherlands and is establishing a presence and team in Europe in order to be closer to the patient community, centers of excellence in medicine and regulatory authorities in regions for which Ms. Hoffmann-Gendebien will manage and oversee at Amylyx. Amylyx will establish its EMEA headquarters in the Zuidas district, Amsterdam, and plans a future expansion into the Middle East and Africa markets.
“At Amylyx, we are determined to help people living with ALS around the world. By expanding our organization in Europe, we can build deeper relationships with local ALS communities and understand their unique needs. With Stéphanie’s extensive global commercial and rare disease experience, and talent for developing long lasting partnerships with advocacy groups, researchers and clinicians, we are confident in her ability to lead Amylyx’ European organization,” said Margaret Olinger, Chief Commercial Officer at Amylyx. “Alongside an already impressive track record, we are certain with Stéphanie’s hands-on leadership style and can-do attitude, she will help us build an incredible team and significant presence across the continent. We’re truly honored to have her join the Amylyx team.”
In her career, Ms. Hoffmann-Gendebien has successfully led the launch of two orphan drugs in Europe and directed global market development, global patient advocacy, European market access and European launch planning for two additional orphan drugs. Most recently, Ms. Hoffmann-Gendebien served as managing director and founding partner of GH PARTNERS, a management consulting company providing consulting services for biotechnology companies involved in rare diseases and orphan drug development. GH PARTNERS provided guidance and consulting to companies related to market development, market access, patient advocacy, general management, orphan drug launch planning and commercialization.
“I was inspired by what I learned about the dedication and urgency with which the entire Amylyx team works to effectively advance AMX0035 through the clinical and commercial development process to help the global ALS community,” said Ms. Hoffmann-Gendebien. “Their willingness to listen and learn from advocacy groups to understand the unique needs of people with ALS is astonishing and makes me proud to join the company. Amylyx is at the forefront of advancing new treatments in neurodegenerative diseases and I am delighted to have the opportunity to develop this organization’s European presence and build out an agile team to serve this market.”
Prior to joining Amylyx, Ms. Hoffmann-Gendebien served as vice president, general manager, Europe, Middle East & Africa (EMEA) at Clementia Pharmaceuticals Inc. Prior to Clementia, she was the European director of strategic market development at Enobia Pharma (Alexion Pharmaceuticals, Inc.) and held roles of increasing responsibility in the therapeutics division Genzyme Europe BV (now Sanofi Genzyme). She serves on the board of directors at Secoya Technologies, a role she has held since April 2020, and volunteers with the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient-driven alliance of rare disease patient organizations. Ms. Hoffmann-Gendebien received a bachelor’s degree in chemistry and an MBA from the Université catholique de Louvain in Louvain-la-Neuve, Belgium.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005775/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
